Your shopping cart is currently empty

KRAS G12C inhibitor 18 is a potent and orally active compound that inhibits KRAS G12C, demonstrating significant anti-tumor activities.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $4,250 | Inquiry | Inquiry |
| Description | KRAS G12C inhibitor 18 is a potent and orally active compound that inhibits KRAS G12C, demonstrating significant anti-tumor activities. |
| In vitro | The compound, KRAS G12C inhibitor 18 (compound 34), effectively suppresses the proliferation of various tumor cell lines harboring the KRas G12C mutation, including H358, SW1436, and MiaPaca-2 cells, among others[1]. |
| In vivo | KRAS G12C inhibitor 18 demonstrates a dose-dependent reduction in pERK and active KRas levels, evident at 8 hours post-administration, with single doses ranging from 12.5 to 100 mg/kg[1]. Additionally, at a dosage of 30 mg/kg administered orally twice daily, it exhibits significant anti-tumor activity in a lung cancer H358 xenograft mouse model[1]. |
| Molecular Weight | 510.97 |
| Formula | C25H20ClFN4O3S |
| Cas No. | 2649788-45-2 |
| Smiles | [H][C@]12CN(CCN1C(=O)c1cc(F)c(c(Cl)c1OCC2)-c1cccc2sc(N)c(C#N)c12)C(=O)C=C |
| Relative Density. | 1.52 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.